New price cuts in Spain will "strangle" pharmaceutical industry
This article was originally published in Scrip
The pharmaceutical industry in Spain is shocked and appalled at new austerity measures in Spain that will introduce yet more price cuts, obligatory prescribing by active ingredient, a reorganisation of the reference pricing system and new ways of determining which drugs to reimburse. They will further risk the future of local companies and SMEs, says Farmaindustria, which represents the R&D-based pharmaceutical industry.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.